GET THE APP

Cell attenuated porcine epidemic diarrhea virus strain Zhejiang08 provides effective immune protection attributed to dendritic cell stimulation
Journal of Antivirals & Antiretrovirals

Journal of Antivirals & Antiretrovirals
Open Access

ISSN: 1948-5964

Cell attenuated porcine epidemic diarrhea virus strain Zhejiang08 provides effective immune protection attributed to dendritic cell stimulation


12th World Congress on Virology

October 16-17, 2017 Baltimore, USA

Yuchen Li and Qian Yang

Nanjing Agricultural University, China

Posters & Accepted Abstracts: J Antivir Antiretrovir

Abstract :

Since 2010, the porcine epidemic diarrhea Coronavirus (PEDV) has caused significant damage to the global pork industry. However, classical PEDV vaccine strains only provide limited protection against emerging strains. In this study, we successfully isolated and attenuated the PEDV epidemic strain Zhejiang08, which was characterized by good cell adaptation and high-titer production 48 h post infection in Vero E6 cells. The attenuated virus induced a high level of virus-specific neutralizing antibodies until 120 days after immunization in piglets and provided complete protection when challenged with an emerging virus strain on day 14 after immunization. Moreover, the capability to activate dendritic cells (DCs) of this isolate was identified. Higher levels of IL-12 and IFN-?³ expression were recorded in DCs treated with Zhejiang08 for 24 h. Furthermore, genome sequencing and phylogenetic analysis revealed that the main antigen epitopes between Zhejiang08 and PEDV pandemic isolates following 2011 were highly homologous. Combining the glycosylation site prediction results and their distribution within the spatial structure of the S protein, led to the conclusion that the more effective host immune response of Zhejiang08 compared to CV777 possibly associated with a lack of the potential glycosylation site in 296 amino acid of the S protein. In summary, we illustrated that the attenuated virus represents a promising vaccine candidate.

Top